Purple Biotech (PPBT) Change in Account Payables (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Change in Account Payables of -$1.2 million for Q1 2026, down 109.97% year-over-year from $12.5 million in Q1 2025, and down 196.13% quarter-over-quarter from $1.3 million in Q4 2025.
Purple Biotech (PPBT) Change in Account Payables (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Change in Account Payables for 10 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 109.97% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$201000.0 (up 92.33% YoY), while the FY2025 annual figure was $450000.0, up 121.68% from the prior year.
- Change in Account Payables eased to -$1.2 million in Q1 2026 per PPBT's latest filing, from $1.3 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.6 million in Q3 2022 and bottomed at -$1.2 million in Q1 2026.
- Historically, Change in Account Payables has averaged -$43294.1 across 5 years, with a median of -$229000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables jumped 1276.81% — and 2025, when it plunged 1186.96%.
- Purple Biotech's Change in Account Payables stood at -$735000.0 in 2022, then surged by 225.03% to $919000.0 in 2023, then tumbled by 148.75% to -$448000.0 in 2024, then soared by 388.62% to $1.3 million in 2025, then plunged by 196.13% to -$1.2 million in 2026.
- Business Quant data shows PPBT's Change in Account Payables at -$1.2 million in Q1 2026, $1.3 million in Q4 2025, and -$22000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - | -506,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.24 Mn |
| Mar 31, 2026 | -1.24 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | -22,000.00 |
| Sep 30, 2025 | -22,000.00 |
| Jun 30, 2025 | -229,000.00 |
| Jun 30, 2025 | -229,000.00 |
| Mar 31, 2025 | -592,000.00 |
| Mar 31, 2025 | -592,000.00 |
| Dec 31, 2024 | -448,000.00 |
| Dec 31, 2024 | -448,000.00 |
| Sep 30, 2024 | -1.14 Mn |
| Sep 30, 2024 | -1.14 Mn |
| Jun 30, 2024 | -444,000.00 |
| Jun 30, 2024 | -444,000.00 |
| Mar 31, 2024 | -46,000.00 |
| Mar 31, 2024 | -46,000.00 |
| Dec 31, 2023 | 919,000.00 |
| Dec 31, 2023 | 919,000.00 |